View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 12, 2021

Sanofi acquires biotech company Tidal Therapeutics for $470m

Sanofi has acquired biotech company Tidal Therapeutics to add an advanced mRNA-based research platform with applications in various disease areas to its portfolio in a deal totalling approximately $470m.

Sanofi has acquired biotech company Tidal Therapeutics to add an advanced mRNA-based research platform with applications in various disease areas to its portfolio in a deal totalling approximately $470m.

According to the transaction, Tidal Therapeutics will get an upfront payment of $160m and is eligible for up to $310m on achieving certain milestones.

The mRNA-based approach for in vivo reprogramming of immune cells will aid in expanding Sanofi’s research capabilities in immuno-oncology and inflammatory diseases, as well as its extended applicability in other disease areas.

Sanofi Research global head and chief scientific officer Frank Nestle said: “We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population.

“We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.”

Based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells in the body, Tidal Therapeutics’ technology provides mRNA cargos selectively to certain types of cells in the body, with initial applications targeting special types of immune cells.

The in vivo approach can potentially offer similar efficacy to existing ex vivo (outside the body) approaches where immune cells are genetically modified to boost their therapeutic properties, thereby possibly enhancing safety, outpatient dosing and repeat dosing.

At present, Tidal Therapeutics is progressing pre-clinical programmes, including in vivo reprogramming of T cells or other immune cell types for cancer indications.

Tidal Therapeutics president and CEO Ulrik Nielsen said: “Teaming up with Sanofi gives us the opportunity to further develop our unique platform and rapidly apply it to ultimately help patients across a range of diseases.”

On another note, Sanofi completed its previously announced acquisition of Kymab Group, adding KY1005 to its pipeline, a fully human monoclonal antibody targeting the key immune system regulator OX40L.

In January, the company signed the agreement to acquire Kymab for an upfront payment of about $1.1bn in cash.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU